Enovis (NYSE:ENOV) SVP Purchases $100,512.00 in Stock

Enovis Corporation (NYSE:ENOV) SVP Bradley Tandy bought 3,200 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of $31.41 per share, with a total value of $100,512.00. Following the completion of the purchase, the senior vice president owned 43,515 shares in the company, valued at approximately $1,366,806.15. This represents a 7.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Enovis Stock Performance

Shares of ENOV stock opened at $31.4080 on Monday. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -2.20 and a beta of 1.70. The stock has a 50 day simple moving average of $30.06 and a 200-day simple moving average of $33.93. Enovis Corporation has a 12-month low of $25.47 and a 12-month high of $49.83. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The business had revenue of $564.50 million for the quarter, compared to analysts’ expectations of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. On average, equities analysts forecast that Enovis Corporation will post 2.79 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Evercore ISI lowered their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. UBS Group lowered their target price on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Friday, August 8th. JMP Securities lowered their target price on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group decreased their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Wells Fargo & Company decreased their price objective on Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a report on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Enovis presently has a consensus rating of “Buy” and an average price target of $51.00.

Institutional Investors Weigh In On Enovis

Several hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System raised its position in shares of Enovis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 52,236 shares of the company’s stock worth $2,292,000 after buying an additional 350 shares during the period. Humankind Investments LLC raised its position in shares of Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after buying an additional 452 shares during the period. US Bancorp DE raised its position in shares of Enovis by 2.5% in the 1st quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after buying an additional 462 shares during the period. Leisure Capital Management raised its position in shares of Enovis by 2.2% in the 1st quarter. Leisure Capital Management now owns 22,903 shares of the company’s stock worth $875,000 after buying an additional 489 shares during the period. Finally, Teacher Retirement System of Texas raised its position in shares of Enovis by 6.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after buying an additional 495 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.